STOCK TITAN
  1. Home
  2. RETA

Reata Pharmaceut (RETA) Stock Price, News & Analysis

RETA NASDAQ
Published by Stock Titan Data refreshed

What Changed

Price Move History

Daily moves over 5%
40 252 sessions, September 26, 2022 to September 26, 2023
Largest daily move
+198.9% close of March 1, 2023
1-year change
+650.4% closing prices, September 26, 2022 to September 26, 2023
1-month change
+2% closing prices, August 25, 2023 to September 26, 2023

Company Description

RETA gained 650.4% in the 12 months to September 26, 2023. The last closing price was $172.36.

This page collects what Stock Titan holds for RETA, including price data and latest news.

Stock Performance

Chart
$172.36
No recent trading
Last close: September 26, 2023
+650.4%
1 year to September 26, 2023
-
Market Cap
-
Shares outstanding

Reata Pharmaceut (RETA) closed at $172.36 on September 26, 2023. In the 12 months to September 26, 2023, the price gained 650.4%.

See what a $1,000 investment in RETA would be worth today

Average down calculator for RETA

RETA Metrics & Rankings

September 2023
+2.0%
—
2023
+353.7%
—

Price returns through September 26, 2023. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

View All
-0.02%

Reata Pharmaceuticals Stockholders Approve Merger Transaction With Biogen Inc.

acquisition
+6.97%

Reata Pharmaceuticals Announces Approval of Prior Approval Supplement for SKYCLARYS® (Omaveloxolone) and Commercial Availability of SKYCLARYS for Patients with Friedreich’s Ataxia

-0.25%

Reata Pharmaceuticals Announces FDA Filing Acceptance of SKYCLARYS® (Omaveloxlone) NDA Prior Approval Supplement

fda approval
+5.24%

Reata Pharmaceuticals Appoints Rajiv Patni, M.D., as Executive Vice President, Chief Research & Development Officer

management
-0.34%

Reata Pharmaceuticals Announces Participation in the Goldman Sachs 44th Annual Global Healthcare Conference

-14.23%

Reata Pharmaceuticals, Inc. Announces First Quarter 2023 Financial Results and Provides an Update on Operational Progress and Clinical Development Programs

earnings clinical trial
+2.20%

Reata Pharmaceuticals, Inc. to Report First Quarter 2023 Financial Results and to Provide an Update on Operational Progress and Clinical Development Programs on May 10, 2023

conferences clinical trial earnings date
-2.60%

Reata Pharmaceuticals Announces Participation in the Barclays Global Healthcare Conference

+198.91%

Reata Pharmaceuticals Announces FDA Approval of SKYCLARYS™ (Omavaloxolone), the First and Only Drug Indicated for Patients with Friedreich’s Ataxia

fda approval
+11.45%

Reata Pharmaceuticals Announces Participation in the Guggenheim 2022 Immunology and Neurology Conference and the Stifel 2022 Healthcare Conference

Reata Pharmaceut has 10 recent news articles. Of the recent coverage, 5 articles coincided with positive price movement and 5 with negative movement. Key topics include acquisition, fda approval, management, earnings, clinical trial. View all RETA news →

SEC Filings

No SEC filings available for RETA.

Frequently Asked Questions

What is the current quoted price of Reata Pharmaceut (RETA)?

Reata Pharmaceut (RETA) has no recent trading. Its last close was $172.36 on September 26, 2023.